Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783588 · ClinicalTrials.gov registry record · Phase 1
A Phase I Extension Trial of Repeated Infusions of ISF35
A Phase 1 study, sponsored by Memgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00783588 is a Phase 1 study that has completed, run by Memgen. The registered enrollment target is 4 participants.
The verdict
NCT00783588, a Phase 1 study, has completed, sponsored by Memgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The study is a Phase Ib extension trial that will assess the toxicity, tolerability, and safety of up to two repeated administrations of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells given intravenously to patients with CLL who tolerated ISF35 in the prior Phase I infusion trial at M.D. Anderson.
Interventions
- BIOLOGICAL ISF35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783588
The ClinicalTrials.gov registry entry for NCT00783588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memgen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISF35 is the first listed.
NCT00783588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783588 about?
NCT00783588 is a clinical study titled "A Phase I Extension Trial of Repeated Infusions of ISF35". The study is a Phase Ib extension trial that will assess the toxicity, tolerability, and safety of up to two repeated administrations of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells given intravenously to patients with CLL who tolerated ISF35 in the prior Phase I infusion ...
What is the current status of trial NCT00783588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2007-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00783588?
The interventions under investigation include: ISF35 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783588?
This trial is sponsored by Memgen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.